Program Book - Confex

More documents

Recommendations

Info

Invited Speaker /Moderator Index 324 Bykerk, Vivian, MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Novartis Pharmaceutical Corporation, 1 C Callahan, Leigh F., PhD Arthritis and Traditional Chinese Medicine . 92 Disclosure: Nothing to Disclose Rubbing Elbows with the Higher Ups: Effective Communications with Administration . . . .117 Disclosure: Nothing to Disclose Callen, Jeffrey P., MD The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Caragher, Timothy E., PhD Practice Potpourri . . . . . . . . . . . . . . .106 Disclosure: Nothing to Disclose Carlson, Hans L., MD Entrapment Neuropathies and Nerve Conduction Studies . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Carter, John D., MD Spondylarthropathies: Recent Insights . . . 88 Disclosure: Nothing to Disclose Carter, Robert H., MD Rheumatoid Arthritis: Where Does It Begin 64 Disclosure: Nothing to Disclose Castillo, Rhina, MD Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose Chang, Alison H., PT, DPT, MS Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Chang, Hyun-Dong, PhD Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . .118 Disclosure: Nothing to Disclose Chen, Lan X., MD, PhD Synovial Fluid Analysis and Crystal Identification . . . . . . . . . . . . . . . . . . . . . . . . . 30 Disclosure: Nothing to Disclose Chhakchhuak, Christine, MD ACR/ARHP Knowledge Bowl . . . . . . . . .113 Disclosure: Nothing to Disclose Chopra, Arvind, MD, DNB ILAR Global Health Project . . . . . . . . . . 81 Disclosure: Nothing to Disclose Christenson, Mary E., PT, PhD Designing Exercise Prescriptions for Individuals with Arthritis and Other Comorbidities: What are the Considerations. . . . . . . . . . . 1115 Disclosure: Nothing to Disclose Lower Extremity Musculoskeletal Assessment of the Rheumatology Patient . . . . . . . . . .129 Disclosure: Nothing to Disclose Christmann, Romy, MD, PhD Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose 2011 Program Book Christopher-Stine, Lisa, MD, MPH Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . 87 Disclosure: Patent, 9 Chu, Cong-Qiu, MD, PhD Entrapment Neuropathies and Nerve Conduction Studies . . . . . . . . . . . . . . 92 Disclosure: Bristol-Myers Squibb, 8; Covidien, 8 Chung, Antanya, CPC, CPC-I, CRHC, CCP ACR Certified Rheumatology Coder Course . 18 Disclosure: Nothing to Disclose ICD-10 & HIPAA 5010 - Ready or Not…It’s Coming! . . . . . . . . . . . . . . . . . . . .116 Disclosure: Nothing to Disclose Clancy, Carolyn M., MD Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers . . 22 Disclosure: Nothing to Disclose Clauw, Daniel J., MD Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . 24 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Lessons Learned from Fibromyalgia Regarding the Mechanisms and Treatment of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . . . 23 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification Disclosure: Nothing to Disclose . . . 30, 59, 87 Clegg, Daniel O., MD Spondylarthropathy: An Update . . . . . . . 27 Disclosure: Nothing to Disclose Clemens, Thomas L., PhD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Clowse, Megan E. B., MD, MPH Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Pregnancy in Rheumatic Diseases . . . . . . 32 Disclosure: Nothing to Disclose Cohen, Stanley B., MD Rheumatoid Arthritis: Difficult Cases . . . .127 Disclosure: Pfizer, Roche, Genentech, Bristol- Myers Squibb, Johnson and Johnson, Centocor, UCB, Merck, Amgen and Novartis, 2, 5 Utilizing Media Relations to Build Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Pfizer, Roche, Genentech, Bristol- Myers Squibb, Johnson and Johnson, Centocor, UCB, Merck, Amgen and Novartis, 2, 5 Conaghan, Philip G., MD, PhD Peripheral Magnetic Resonance Imaging in Rheumatology Practice . . . . . . . . . . . . 30 Disclosure: Amgen, 5; AstraZeneca, 8; Bioiberica, 8; Bristol-Myers Squibb, 5; Centocor, Inc., 2; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2; Roche Pharmaceuticals, 5 Cooper, Glinda S., PhD ICD Coding - Crash Course for Researchers . 54 Disclosure: Nothing to Disclose Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Costenbader, Karen H., MD, MPH Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Rheumatoid Arthritis: Where Does it Begin 64 Disclosure: Nothing to Disclose Coty, Mary-Beth, PhD, RN Cognitive Function in Systemic Lupus Erythematosus. . . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Cox, Talitha, MA, OTR/L Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose Crawford, Donah Z., BS, MA Highlights from the 2011 ARHP Sessions . .117 Disclosure: Nothing to Disclose Criswell, Lindsey A., MD, MPH Mechanisms of Lymphoma Development in Systemic Autoimmune Disease. . . . . . . . 95 Disclosure: Nothing to Disclose Crofford, Leslie J., MD Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose Gender Issues in the Rheumatology Workforce . . . . . . . . . . . . . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Year in Review . . . . . . . . . . . . . . . . . 26 Disclosure: Nothing to Disclose Cronin, Mary E., MD Adult Inflammatory Myopathy . . . . . . . . 32 Disclosure: Nothing to Disclose Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose Cronstein, Bruce N., MD Adult Pharmacogenomics . . . . . . . . . . 89 Disclosure: Canfite Pharma; Bristol-Myers Squibb; Tap Pharmaceuticals; Prometheus laboratories; Regeneration (Westat, DSMB); Endocyte; Savient. , 5; Canfite Piophamaceuticals, 1; Eli Lilly & Co.; UCB , Pfizer,Vilcek Foundation, 6; NIH; Vilcek Foundation; URL Pharma, 2 Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Canfite Pharma; Bristol-Myers Squibb; Tap Pharmaceuticals; Prometheus laboratories; Regeneration (Westat, DSMB); Endocyte; Savient. , 5; Canfite Piophamaceuticals, 1; Eli Lilly & Co.; UCB ;Pfizer; Vilcek Foundation, 6; NIH; Vilcek Foundation; URL Pharma, 2
Cush, John J., MD Rheumatology Roundup: Highlights from the 2011 Annual Scientific Meeting . . . . . . .111 Disclosure: Abbott Immunology Pharmaceuticals, 5; Allos, 5; Amgen, 5; Auxilum, 5; Celgene, 5; Cellestis, 5; Centorcor, 5; Flexion, 5; Genentech and Biogen IDEC Inc., 5; Human Genome Sen, 5; Ortho Biotech Products L.P., 5; Pfizer Inc, 5; UCB, 2, 4 D Dahl, Owen J., MBA, CHBC Mastering Patient Flow to Improve Practice Operations . . . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Daikh, Brian E., MD Thieves’ Market: Show Me Your Best Cases. 71 Disclosure: Nothing to Disclose Daikh, David I, MD, PhD ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose Dasgupta, Bhaskar, MD Polymyalgia Rheumatica . . . . . . . . . . . 32 Disclosure: Nothing to Disclose Davey, Michael P., MD, PhD Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular . . . . . . . . . . . . . . . . .105 Disclosure: Nothing to Disclose Davidson, Anne, MBBS ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . .104 Disclosure: Abbott Immunology Pharmaceuticals, 5; Bristol-Myers Squibb, 5 De Vries, Niek, MD, PhD Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Deal, Chad L., MD Great Debate: Is too Much Suppression of Turnover Bad for Bone. . . . . . . . . . . . 42 Disclosure: Lilly, Novartis, Amgen, 5; Lilly, Novartis, Amgen, Warner Chilcott, 8 Deane, Kevin D., MD, PhD Rheumatoid Arthritis: Where Does It Begin 64 Disclosure: Abbott Laboratories, 2 Dees, Clara, MSc Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Del Fatore, Andrea, PhD Plenary Session II . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Dellaripa, Paul F., MD Pulmonary Manifestations of Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . 62 Disclosure: BIogen, Gilead, 2, 9 Pulmonary Manifestations of Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . 93 Disclosure: Nothing to Disclose Dennis, Gregory J., MD Contract Negotiations for Physicians . . . . 62 Disclosure: Nothing to Disclose Denton, Christopher P., PhD Scleroderma: Systemic Sclerosis . . . . . 87, 56 Disclosure: Actelion Pharmaceuticals US, 5; GSK, 5; Orion pharmaceuticals, 5; Pfizer Inc, 5; Sanofi- Aventis Pharmaceutical, 5 Denton, G. Dodd, MD, MPH Medical Education: Year in Review. . . . . . 33 Disclosure: Nothing to Disclose Deodhar, Atul A., MD, MRCP Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease . . . 72 Disclosure: Nothing to Disclose Joint Injection Techniques . . . . . . . . . . 30 Disclosure: Nothing to Disclose Reactive Arthritis: An Update . . . . . . . . 80 Disclosure: Centocor, Inc., 5, 8 Deutsch, Anne, RN, PhD, CRRN Analysis of Large Databases: Rheumatology Research Opportunities. . . . . . . . . . . .124 Disclosure: Nothing to Disclose Dewing, Kori A., DNP, ARNP ARHP Distinguished Lecturer: How Do We Get Policy Makers to Take Musculoskeletal Conditions Seriously – The Bone and Joint Initiative . . . . . . . . . . . . . . . . . . . . 59 Disclosure: Nothing to Disclose Keynote Address: Sleep for Success! Everything You Must Know About Sleep, but Are Too Tired to Ask. . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Metabolic Bone Disease . . . . . . . . . . .115 Disclosure: Nothing to Disclose Dixon, William G., MRCP, PhD Heart Disease and Rheumatoid Arthritis . . 74 Disclosure: Nothing to Disclose Dodge, Carole V., OT, CHT Pregnancy and Child Care Issues for Parents with Arthritis. . . . . . . . . . . . . . . . . . 89 Disclosure: Nothing to Disclose Dooley, M.A., MD, MPH Systemic Lupus Erythematosus: Novel Treatments. . . . . . . . . . . . . . . . . . .100 Disclosure: Human Genome Sciences, GlaxoSmithKline, Vifor Pharma, Lupus Foundation of America Medical Scientific and Advisory Board, 5; Human Genome Sciences, UCB, Genentech, Cephalon, Bristol-Myers Squibb, Eli Lilly, 2 Dore, Robin K., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . .123 Disclosure: Amgen, Takeda, UCB, Roche, Sanofe- Aventis, Eli Lilly, Bristol-Meyers, Squibb reserch grants. Consulting fees for Amgen, Novartis, Takeda, Pfizer, Abbott. Speaker’s bureau for Amgen, Pfizer, UCB, Abbott, Takeda, Novartis, Eli Lilly, Warner-Chilcott, 8 Dowell, Sharon, MBBS Thieves’ Market: Show Me Your Best Cases. 71 Disclosure: Nothing to Disclose Dufour, Alyssa B., MA Are You Losing It How to Deal with Loss to Follow Up in Research Studies and Clinical Trials 92 Disclosure: Nothing to Disclose Dugan, Sheila A., MD Gender Issues in the Rheumatology Workforce . . . . . . . . . . . . . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Duruoz, Mehmet Tuncay, MD Axial Spondylarthritis: New Concepts . . . . 53 Disclosure: Nothing to Disclose E Ehrlich-Jones, Linda S., PhD, RN First-time Attendees Orientation . . . . . . 26 Disclosure: Nothing to Disclose Policy and Environmental Strategies to Support Increased Physical Activity for Adults with Arthritis: Findings from a Centers for Disease Control/Arthritis Foundation Expert Panel .129 Disclosure: Nothing to Disclose Rubbing Elbows with the Higher Ups: Effective Communications with Administration . . . .117 Disclosure: Nothing to Disclose Eich, Geoffrey Biosimilar Products in the U.S. Market: Fact or Fiction. . . . . . . . . . . . . . . . . . . . .125 Disclosure: Full Time Employee, 3 El-Gabalawy, Hani S., MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Elkon, Keith B., MD Apoptosis, Phagocytic Clearance and Autoimmune and Inflammatory Diseases . .116 Disclosure: Resolve Therapeutics, 2 Embi, Peter J., MD, MS Designing a Website for Your Practice . . . . 30 Disclosure: Nothing to Disclose Epstein, Alana, MSW Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Erickson, Alan R., MD CORC Forum: Payment Reform Options . . 92 Disclosure: Nothing to Disclose Erkan, Doruk, MD Management of Antiphospholipid Syndrome- From Controversies to Consensus . . . . . . 44 Disclosure: Genentech and Biogen IDEC Inc., 2, 5; Lupus Clinical Trials Consortium, 2 Espinoza, Luis R., MD ILAR Global Health Project . . . . . . . . . . 80 Disclosure: Nothing to Disclose 2011 Program Book 325 Invited Speaker /Moderator Index
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS POLICIES Copyrigh
Page 7 and 8:
TABLE OF CONTENTS ACR Immunology Up
Page 9 and 10:
TABLE OF CONTENTS Vasculitis Poster
Page 11 and 12:
However, the ACR continues to requi
Page 13 and 14:
MEETING NAVIGATION GUIDE To navigat
Page 15 and 16:
Newsroom Located in room W175c, use
Page 17:
Guided Poster Tours Guided poster t
Page 20 and 21:
FRIDAY November 4, 2011 9:15 am Ult
Page 22 and 23:
SATURDAY, NOVEMBER 5, 2011 12:00 -
Page 24 and 25:
SATURDAY November 5, 2011 8:35 am T
Page 26 and 27:
SATURDAY November 5, 2011 Pain: Pat
Page 28 and 29:
SUNDAY November 6, 2011 SUNDAY, NOV
Page 30 and 31:
SUNDAY November 6, 2011 Upon comple
Page 32 and 33:
EXHIBITS 10:00 am - 5:00 pm INNOVAT
Page 34 and 35:
SUNDAY November 6, 2011 ARHP SPECIA
Page 36 and 37:
SUNDAY November 6, 2011 W179b Rheum
Page 38 and 39:
3:15 pm 732. Notch Signaling Pathwa
Page 40 and 41:
SUNDAY November 6, 2011 3:15 pm 756
Page 42 and 43:
SUNDAY November 6, 2011 Children’
Page 44 and 45:
Page 46 and 47:
3:30 pm Demonstration and Practice
Page 48 and 49:
Yasser M. El Miedany 1 , Maha El Ga
Page 50 and 51:
SUNDAY November 6, 2011 48 Musculos
Page 52 and 53:
Page 54 and 55:
SUNDAY November 6, 2011 52 4:55 pm
Page 56 and 57:
MONDAY, NOVEMBER 7, 2011 ACR/ARHP R
Page 58 and 59:
MONDAY November 7, 2011 W185a Scler
Page 60 and 61:
MONDAY November 7, 2011 Upon comple
Page 62 and 63:
Upon completion of this session, pa
Page 64 and 65:
MONDAY November 7, 2011 W187b Basic
Page 66 and 67:
MONDAY November 7, 2011 2:30 pm Cel
Page 68 and 69:
MONDAY November 7, 2011 Indianapoli
Page 70 and 71:
3:45 pm 1628. Association of Knee P
Page 72 and 73:
MONDAY November 7, 2011 Glostrup, C
Page 74 and 75:
MONDAY November 7, 2011 3:33 pm A R
Page 76 and 77:
MONDAY November 7, 2011 4:30 pm Ris
Page 78 and 79:
Institutet, Stockholm, Sweden, 6 Un
Page 80 and 81:
5:45 pm 1700. Successful Dose De-Es
Page 82 and 83:
MONDAY November 7, 2011 Michigan, A
Page 84 and 85:
MONDAY November 7, 2011 4:45 pm 172
Page 86 and 87:
MONDAY November 7, 2011 5:25 pm Imp
Page 88 and 89:
TUESDAY November 8, 2011 ARHP CONCU
Page 90 and 91:
TUESDAY November 8, 2011 9:25 am Is
Page 92 and 93:
ACR PRACTICE ISSUE 9:30 - 10:30 am
Page 94 and 95:
TUESDAY November 8, 2011 noon 2431.
Page 96 and 97:
TUESDAY November 8, 2011 W186b Vasc
Page 98 and 99:
ACR CLINICAL SYMPOSIA 2:30 - 4:00 p
Page 100 and 101:
TUESDAY November 8, 2011 3:45 pm 24
Page 102 and 103:
TUESDAY November 8, 2011 University
Page 104 and 105:
TUESDAY November 8, 2011 and Oncolo
Page 106 and 107:
Italy, 3 Hospital Universitario La
Page 108 and 109:
3:10 pm Case Study Diane V. Lacaill
Page 110 and 111:
• discuss the evidence to support
Page 112 and 113:
TUESDAY November 8, 2011 4:45 pm 25
Page 114 and 115:
5:15 pm 2532. Selection of Patients
Page 116 and 117:
TUESDAY November 8, 2011 ACR/ARHP C
Page 118 and 119:
WEDNESDAY, NOVEMBER 9, 2011 ACR/ARH
Page 120 and 121:
9:00 am Mechanisms of Thrombosis in
Page 122 and 123:
WEDNESDAY November 9, 2011 A. Kopec
Page 124 and 125:
WEDNESDAY November 9, 2011 9:15 am
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
WEDNESDAY November 9, 2011 Graduate
Page 132 and 133:
11:00 am The Process: Defining Appr
Page 134 and 135:
ACR Poster Session A 11. Myocardial
Page 136 and 137:
ACR Poster Session A 37. Regulation
Page 138 and 139:
ACR Poster Session A 64. Interleuki
Page 140 and 141:
ACR Poster Session A Mexico City, M
Page 142 and 143:
ACR Poster Session A 121. An Analys
Page 144 and 145:
ACR Poster Session A 146. National
Page 146 and 147:
ACR Poster Session A 165. Genome-Wi
Page 148 and 149:
ACR Poster Session A 185. US Examin
Page 150 and 151:
ACR Poster Session A Jones 1 , Andr
Page 152 and 153:
ACR Poster Session A Gerald J. D. H
Page 154 and 155:
ACR Poster Session A 258. Etanercep
Page 156 and 157:
ACR Poster Session A GA, 6 Hospital
Page 158 and 159:
ACR Poster Session A 305. Pathway-B
Page 160 and 161:
ACR Poster Session A 328. Near Miss
Page 162 and 163:
ACR Poster Session A 351. A Novel M
Page 164 and 165:
ACR Poster Session A Sugihara 6 , K
Page 166 and 167:
ACR Poster Session A 398. Rituximab
Page 168 and 169:
ACR Poster Session A & Johnson Phar
Page 170 and 171:
ACR Poster Session A 436. Predicted
Page 172 and 173:
ACR Poster Session A Tomomi Tsuru 1
Page 174 and 175:
ACR Poster Session A 479. Follow up
Page 176 and 177:
ACR Poster Session A 496. A Chimeri
Page 178 and 179:
ACR Poster Session A 518. Associati
Page 180 and 181:
ACR Poster Session A Piestany, Slov
Page 182 and 183:
ACR Poster Session A 576. Fn14 Defi
Page 184 and 185:
ACR Poster Session A 593. Plasma Le
Page 186 and 187:
ACR Poster Session A 611. Why Do Lu
Page 188 and 189:
ACR Poster Session A 634. Associati
Page 190 and 191:
ACR Poster Session A Alarcon-Riquel
Page 192 and 193:
ACR Poster Session A Laboratories,
Page 194 and 195:
ACR Poster Session A Movsisyan, Lid
Page 196 and 197:
ACR Poster Session A Th1 Cells Expa
Page 198 and 199:
ACR/ARHP Poster Session B College o
Page 200 and 201:
ACR/ARHP Poster Session B 920. Econ
Page 202 and 203:
ACR/ARHP Poster Session B Study. A.
Page 204 and 205:
ACR/ARHP Poster Session B 974. Dise
Page 206 and 207:
ACR/ARHP Poster Session B 1001. Mic
Page 208 and 209:
ACR/ARHP Poster Session B 206 Khann
Page 210 and 211:
ACR/ARHP Poster Session B 208 Pulmo
Page 212 and 213:
ACR/ARHP Poster Session B Swearinge
Page 214 and 215:
ACR/ARHP Poster Session B 212 Felds
Page 216 and 217:
ACR/ARHP Poster Session B 214 Corbi
Page 218 and 219:
ACR/ARHP Poster Session B 1161. End
Page 220 and 221:
ACR/ARHP Poster Session B 1182. Uri
Page 222 and 223:
ACR/ARHP Poster Session B 1205. A S
Page 224 and 225:
ACR/ARHP Poster Session B 222 Murth
Page 226 and 227:
ACR/ARHP Poster Session B San Diego
Page 228 and 229:
ACR/ARHP Poster Session B 1266. Eva
Page 230 and 231:
ACR/ARHP Poster Session B 1296. Pat
Page 232 and 233:
ACR/ARHP Poster Session B 230 1320.
Page 234 and 235:
ACR/ARHP Poster Session B 1348. Syn
Page 236 and 237:
ACR/ARHP Poster Session B 1375. Ant
Page 238 and 239:
ACR/ARHP Poster Session B 1398. Cli
Page 240 and 241:
ACR/ARHP Poster Session B Baltimore
Page 242 and 243:
ACR/ARHP Poster Session B 1451. Ele
Page 244 and 245:
ACR/ARHP Poster Session B Sclerosis
Page 246 and 247:
ACR/ARHP Poster Session B 1496. Evi
Page 248 and 249:
ACR/ARHP Poster Session B 1518. Pro
Page 250 and 251:
ACR/ARHP Poster Session B Hagen 1 ,
Page 252 and 253:
ACR/ARHP Poster Session B ARHP Clin
Page 254 and 255:
ACR/ARHP Poster Session C Karl Eger
Page 256 and 257:
ACR/ARHP Poster Session C Tampere S
Page 258 and 259:
ACR/ARHP Poster Session C 256 1 Jun
Page 260 and 261:
ACR/ARHP Poster Session C Universit
Page 262 and 263:
ACR/ARHP Poster Session C 1864. Epi
Page 264 and 265:
ACR/ARHP Poster Session C 262 Hospi
Page 266 and 267:
ACR/ARHP Poster Session C 2 Biogen
Page 268 and 269:
ACR/ARHP Poster Session C 1945. Cir
Page 270 and 271:
ACR/ARHP Poster Session C 268 1974.
Page 272 and 273:
ACR/ARHP Poster Session C 2003. Eff
Page 274 and 275:
ACR/ARHP Poster Session C Hosp Gast
Page 276 and 277: ACR/ARHP Poster Session C Toronto,
Page 278 and 279: ACR/ARHP Poster Session C Francisco
Page 280 and 281: ACR/ARHP Poster Session C 2105. Inc
Page 282 and 283: ACR/ARHP Poster Session C Universit
Page 284 and 285: ACR/ARHP Poster Session C 282 2151.
Page 290 and 291: ACR/ARHP Poster Session C 2217. Lon
Page 292 and 293: ACR/ARHP Poster Session C Research
Page 294 and 295: ACR/ARHP Poster Session C 2258. sIL
Page 296 and 297: ACR/ARHP Poster Session C 2290. The
Page 298 and 299: ACR/ARHP Poster Session C Universit
Page 300 and 301: ACR/ARHP Poster Session C 2345. IL-
Page 302 and 303: ACR/ARHP Poster Session C 2376. Gra
Page 304 and 305: ACR/ARHP Poster Session C 2399. Spe
Page 306 and 307: REF Industry Roundtable-supported S
Page 308 and 309: REF Industry Roundtable-supported S
Page 310 and 311: Industry-supported POST-CONFERENCE
Page 312 and 313: CERTIFICATES OF CME CREDIT OR PARTI
Page 314 and 315: 2011 ACR/ARHP Annual Meeting Leader
Page 316 and 317: 2011 ACR/ARHP Annual Meeting Leader
Page 318 and 319: EXHIBITORS Abbott Pharmaceuticals B
Page 320 and 321: EXHIBITORS Lippincott, Williams and
Page 322 and 323: acknowledgements The ACR, the ARHP
Page 324 and 325: Invited Speaker /Moderator Index 32
Page 328 and 329: Invited Speaker /Moderator Index Ev
Page 334 and 335: Invited Speaker /Moderator Index Mu
Page 336 and 337: Invited Speaker /Moderator Index Om
Page 338 and 339: Invited Speaker /Moderator Index St
Page 340 and 341: Invited Speaker /Moderator Index Wi
Page 342 and 343: aBSTRACT author Index 340 Alpers, C
Page 344 and 345: aBSTRACT author Index Bawa, WA 259
Page 346 and 347: aBSTRACT author Index 344 Broder, A
Page 348 and 349: aBSTRACT author Index 346 Chaves, L
Page 350 and 351: aBSTRACT author Index 348 Dalbeth,
Page 352 and 353: aBSTRACT author Index Eastman, PS 3
Page 354 and 355: aBSTRACT author Index 352 Fragoso-L
Page 356 and 357: aBSTRACT author Index Gordon, C 4,
Page 358 and 359: aBSTRACT author Index Hemmati, I 13
Page 360 and 361: aBSTRACT author Index 358 Ishigatsu
Page 362 and 363: aBSTRACT author Index 360 Keeling,
Page 364 and 365: aBSTRACT author Index 362 Kumar, V
Page 366 and 367: aBSTRACT author Index 364 Lim, M 13
Page 368 and 369: aBSTRACT author Index 366 Marshall,
Page 370 and 371: aBSTRACT author Index 368 MMF/AZA L
Page 372 and 373: aBSTRACT author Index 370 Noel, D 1
Page 374 and 375: aBSTRACT author Index 372 Pawlita,
Page 376 and 377:
aBSTRACT author Index 374 Ramos, I
Page 378 and 379:
aBSTRACT author Index 376 Rönnblom
Page 380 and 381:
aBSTRACT author Index 378 Shaykevic
Page 382 and 383:
aBSTRACT author Index Su, J 22, 139
Page 384 and 385:
aBSTRACT author Index 382 Tomcik, M
Page 386 and 387:
aBSTRACT author Index 384 Villeneuv
Page 388 and 389:
aBSTRACT author Index 386 Wu, X 650
Page 390 and 391:
abstract keyword Index 388 18FDG PE
Page 392 and 393:
abstract keyword Index 2092, 2113,
Page 394 and 395:
abstract keyword Index 392 macropha
Page 396 and 397:
abstract keyword Index 387, 388, 38
Page 398 and 399:
Abstract Moderator disclosure A Ano
Page 400 and 401:
Abstract Moderator disclosure Jonas
Page 402 and 403:
V van der Heijde, Desiree, MD, PhD
Page 404 and 405:
Notes 402 2011 Program Book
Page 406 and 407:
immunosuppressive agents is not rec
Page 408:
In appropriate patients with psoria
show all

Program Book - Confex

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?